Plain-English translation of NCT06197672 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called T cells—your own immune cells that are taken from your body, genetically modified in a lab to recognize and attack leukemia cells, and then given back to you. This treatment is designed for people whose acute myeloid leukemia (a type of blood cancer) has not responded to standard chemotherapy and is intended to help control the disease until you can receive a stem cell transplant.
Many people with acute myeloid leukemia do not respond well to standard treatments, and doctors need new options to help control the disease and prepare patients for a potentially curative stem cell transplant. This trial is testing whether genetically engineered immune cells can be more effective at fighting this aggressive cancer.
You likely qualify if…
You likely don't qualify if…
First, doctors will check your disease status and then collect a large number of your immune cells through a procedure similar to a blood donation. Your cells will be sent to a lab where they are genetically engineered over several weeks. While your cells are being prepared, you'll receive chemotherapy to prepare your body. Once ready, you'll receive an infusion of your engineered cells on Day 0. After that, you'll have frequent blood tests and clinic visits over the following weeks and months to monitor how well the treatment is working, measure levels of engineered cells in your blood, and watch for any side effects.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States